Table 1.

Correlation of mutation status of cell lines and response to cetuximab

Cell line% Inhibition relative to control (mean ± SE)Mutant K-Ras Ex 2Mutant BRAF exon 15Mutant PIK3CA exon 9Mutant PIK3CA exon 20Mutant total PIK3CAPTEN nullMutant RAS/BRAFMutant PIK3CA/PTENRAS/BRAF and PIK3CA/PTEN mutant
LIM1215 *79.6 ± 3.5
GEO 68.7 ± 1.6++
SW403 66.0 ± 4.9++
CAC02 47.7 ± 4.3
SW948 42.7 ± 1.4+++
HT29 36.5 ± 8.2++
SKCO1 33.9 ± 3.5++
RW2982 *33.0 ± 1.3
HCT8 *27.1 ± 4.0++++++
DLD 24.9 ± 7.4++++++
SW480 23.7 ± 3.0++
SW837 21.8 ± 8.5++
SW48 21.8 ± 1.2
RKO 21.2 ± 6.9++++++
HCC2998 , §15.2 ± 3.3
SW620 14.5 ± 2.2++
LS174T 13.0 ± 3.9++++++
T84 11.2 ± 9.2++++++
KM12 7.1 ± 9.1+++++
HCT15 4.5 ± 6.5++++++
LIM2405 *2.0 ± 2.2+++++
HCT116 −14.1 ± 1.3++++++
  • NOTE: Sensitivity of the cell line panel to cetuximab treatment and mutation status of PIK3CA, BRAF, and K-Ras and expression status of PTEN in colon cancer cell line panel. Values shown are mean ± SE at the 20 μg/mL dose of cetuximab, 72 h posttreatment (n = 3–5).

  • * Present study.

  • Ras/BRAF from cosmic; PIK3CA by present study.

  • From cosmic database, http://www.sanger.ac.uk/genetics/CGP/cosmic/.

  • § Mutations in p85α ( 49) and in codon 146 of K-Ras ( 48) have been reported in this cell line.